Loading...

Ultra-LEAF™ Purified anti-human CD152 (CTLA-4) Antibody

Pricing & Availability
Clone
W22041G (See other available formats)
Regulatory Status
RUO
Other Names
Cytotoxic T-CD152, CELIAC3, GSE, IDDM12
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
W22041G_ULEAF_CD152_Block_092624
Biotinylated recombinant human CTLA-4- Fc chimera (Cat. No. 786704) (black circles) binds to immobilized recombinant human B7-2/CD86-Fc chimera (Cat. No. 775604). Ultra-LEAF™ purified anti-human CD152 (CTLA-4) (clone W22041G) (purple squares) inhibits the binding in a dose-dependent manner, whereas the Ultra-LEAF™ purified rat IgG2a, κ isotype control (Cat. No. 400544) (gray triangles) does not have effect. This antibody blocks the binding of 0.15 µg/mL biotinylated human CTLA-Fc chimera to 1 µg/mL immobilized recombinant human B7-2/CD86-Fc chimera. ND50 range: 0.07 - 0.5 μg/mL.
  • W22041G_ULEAF_CD152_Block_092624
    Biotinylated recombinant human CTLA-4- Fc chimera (Cat. No. 786704) (black circles) binds to immobilized recombinant human B7-2/CD86-Fc chimera (Cat. No. 775604). Ultra-LEAF™ purified anti-human CD152 (CTLA-4) (clone W22041G) (purple squares) inhibits the binding in a dose-dependent manner, whereas the Ultra-LEAF™ purified rat IgG2a, κ isotype control (Cat. No. 400544) (gray triangles) does not have effect. This antibody blocks the binding of 0.15 µg/mL biotinylated human CTLA-Fc chimera to 1 µg/mL immobilized recombinant human B7-2/CD86-Fc chimera. ND50 range: 0.07 - 0.5 μg/mL.
  • W22041G_ULEAF_CD152_Block-2_061224
    Recombinant human CTLA-4-Fc chimera (Cat. No. 591904) (black circles) inhibits the production of human IL-2 induced by human B7.1 (CD80)-Fc in Jurkat cells. Ultra-LEAF™ purified anti-human CD152 (CTLA-4) (clone W22041G) (purple squares) neutralizes the inhibition effect of recombinant human CTLA-4-Fc chimera (Cat. No. 591904) at 0.1 µg /mL on production of human IL-2 induced by human B7.1 (CD80)-Fc in Jurkat cells in a dose-dependent manner whereas the Ultra-LEAF™ purified rat IgG2a, κ isotype control (gray triangles) (Cat. No. 400544) does not have effect. ND50 range: 0.75 - 4 µg/mL.
Cat # Size Price Quantity Check Availability Save
638153 100 µg 336€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
638154 1 mg 852€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a member of the IgG superfamily. It encodes a 223 amino acid protein and possesses a single extracellular V domain, a transmembrane domain, and a cytoplasmic domain. CTLA-4 is ~30% homologous with CD28, and both bind to the same ligands (B7.1/CD80 and B7.2/CD86) although CTLA-4 binds with higher affinity than CD28. Parallel recognition of a specific MHC-peptide complex by the T-cell receptor and of CD80 or CD86 by the costimulatory receptor CD28 results in T-cell activation, cytokine production, proliferation, and differentiation. After T cell activation process and upregulation of CTLA-4, co-ligation of the TCR to MHC-peptide complex and CTLA-4 to its ligands results in cell cycle arrest and ends T cell activation. It has been suggested that the negative regulatory mechanism of CTLA-4 is mediated through trans-endocytosis of CD80 and CD86 (capture of ligands from opposing cells). The ligands are removed from the original cell and degraded inside of CTLA-4-expressing cells. As a result, the action of CD28 is impaired. Alternative splice variants of CTLA-4 have been described in mouse and human that have transcripts that skip exon 2 (ligand-binding domain) or exon 3 (transmembrane domain). The ligand independent CTLA-4 is expressed in mice, but not in humans, and soluble CTLA-4 (sCTLA-4) is expressed in mice and humans. CTLA-4 is constitutively expressed by Tregs, and they are an important source of sCTLA-4. It has been suggested that sCTLA-4 potentiates regulatory T cell function. High levels of sCTLA-4 in Tregs have been associated with type 1 diabetes (T1D) and other autoimmune diseases, such as Grave's disease and myasthenia gravis. Also, CTLA-4 has been linked with proliferation and survival of chronic lymphocytic leukemia. CTLA-4 is a target for therapeutic intervention; in fact, a monoclonal antibody against CTLA-4 (Ipilimumab) has been approved for the treatment of melanoma.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant Human CTLA-4-Fc chimera
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/μg of the protein (less than 0.001 ng/μg of the protein) as determined by the LAL test
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

Block - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by blocking the binding of 0.15 µg/mL recombinant biotinylated human CTLA-4-Fc (Cat. No. 786704) to immobilized 1 µg/mL recombinant human B7-2/CD86-Fc chimera (Cat. No. 775604). ND50 range: 0.07 - 0.5 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.

Antigen Details

Structure
Homodimer
Distribution

Activated T cells, CD4, CD8, and Tregs

Function
Inhibits T cell activation by reducing IL-2 production and IL-2R expression, also arresting T cells in G1 phase of the cell cycle; protects against the development of autoimmunity.
Interaction
Antigen presenting cells, B cells
Ligand/Receptor
CD80 (B7.1), CD86 (B7.2)
Cell Type
B cells, T cells, Tregs
Biology Area
Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References
  1. Linsley PS, et al. 1991. J Exp Med. 174:561-9. 
  2. Pentcheva-Hoang T, et al. 2004. Immunity. 2:401-13.
  3. Qureshi OS, et al. 2011. Science. 332:600-3.
  4. Gerold KD, et al. 2011. Diabetes. 60:1955-63.
  5. Ryden A, et al. 2012. Diabetes Metab Res Rev. 28:84-96.
  6. Mittal AK, et al. 2013. PloS One. 8:e70352.
  7. Ward FJ, et al. 2013. Eur J Immunol. 43:1274-85.
Gene ID
1493 View all products for this Gene ID
UniProt
View information about CD152 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 1    Revision Date: 05.22.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account